Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Topotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Hycamtin, Topotecan, Topotecan Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Topotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Carcinoma
  • Cervical adenocarcinoma
  • Cervical cancer
  • Cervical carcinoma
  • Ovarian cancer
  • Ovarian neoplasm
  • Small cell carcinoma
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Topotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Topotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Use of Topotecan in Patients With Refractory Acute Leukemia

    NCT00100477 · start 1998-08

    Registered record
    Registry ID
    NCT00100477
    Conditions
    Non-Hodgkin's Lymphoma; Leukemia
    Interventions
    Topotecan; Mitozantrone; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-08
    Completion
    2001-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin's Lymphoma; Leukemia
    InterventionTopotecan; Mitozantrone; Etoposide
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

    NCT00003619 · start 1998-02

    Registered record
    Registry ID
    NCT00003619
    Conditions
    Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Thrombocytopenia
    Interventions
    filgrastim; vitamin E; busulfan; cytarabine; etoposide; fludarabine phosphate; isotretinoin; topotecan hydrochloride; bone marrow ablation with stem cell support; peripheral blood stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    1998-02
    Completion
    2004-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Thrombocytopenia
    Interventionfilgrastim; vitamin E; busulfan; cytarabine +6 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Therapy for Children With Advanced Stage High Risk Neuroblastoma

    NCT00186849 · start 1997-10

    Registered record
    Registry ID
    NCT00186849
    Conditions
    Neuroblastoma
    Interventions
    Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin; Peripheral Blood Stem Cell Transplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-10
    Completion
    2001-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionTopotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin; Peripheral Blood Stem Cell Transplant
    PhasePhase 2
    Registry statusCompleted

  • Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

    NCT00002734 · start 1996-03

    Registered record
    Registry ID
    NCT00002734
    Conditions
    Ovarian Cancer; Primary Peritoneal Cavity Cancer
    Interventions
    recombinant interferon alfa; chemotherapy; paclitaxel; topotecan hydrochloride; lutetium Lu 177 monoclonal antibody CC49; yttrium Y 90 monoclonal antibody CC49
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1996-03
    Completion
    Not recorded
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Primary Peritoneal Cavity Cancer
    Interventionrecombinant interferon alfa; chemotherapy; paclitaxel; topotecan hydrochloride +2 more
    PhasePhase 1
    Registry statusCompleted

  • Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

    NCT00002537 · start 1993-09

    Registered record
    Registry ID
    NCT00002537
    Conditions
    Lung Cancer
    Interventions
    topotecan hydrochloride; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1993-09
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    Interventiontopotecan hydrochloride; radiation therapy
    PhasePhase 1
    Registry statusCompleted